Mark Garret, MD
Neurology · Lebanon, NHNPI 1245683226
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $121 of the $149 with a category attached, or 80.9%. Genentech USA, Inc. accounts for 80.9% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for neurology clinicians in NH, where the typical reported total is $213.
Across 2 payments — averaging $74.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$121
- Tanabe Pharma America, Inc.$28
Across 2 payments — averaging $135,031 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$270K
What the payments were for
- Food & beverage$12181%
- Education$2819%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 1 | $121 |
| Tanabe Pharma America, Inc. | 1 | $28 |
How this compares
$149 in reported general payments places this provider in the 40th percentile of 92 neurology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 240 | $3,408,126 |
| RelyvrioSod Phenylbutyrat/Taurursodiol | 33 | $404,331 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 12 | $154,075 |
| NuedextaDextromethorphan Hbr/Quinidine | 20 | $29,504 |
| Riluzole | 128 | $21,836 |
| Glycopyrrolate | 13 | $996 |
| Gabapentin | 42 | $897 |
| Tizanidine Hcl | 18 | $731 |
| Baclofen | 39 | $687 |
| Atropine Sulfate | 24 | $523 |
| Cyclobenzaprine Hcl | 11 | $341 |
Paid to pharmacies, not to this prescriber.
Other neurology in Lebanon
- Oliver PhillipsLebanon$50K
- Andrew PachnerLebanon$31K
- Jeffrey CohenLebanon$18K
- Jianhui ZhangLebanon$12K
- Francis BenzLebanon$8K
- Thomas WardLebanon$5K
- Diana LiLebanon$4K
- Steven CherryLebanon$2K
- Timothy LukovitsLebanon$2K
- Nicole OdomLebanon$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.